You are here

Vraylar

AbbVie makes Richter richer, paying $25M to form discovery pact with Vraylar originator

Fierce Biotech

Fri, 10/25/24 - 11:37 am

Could This FDA Approval Boost AbbVie's Stock?

Motley Fool

Wed, 01/18/23 - 09:49 am

major depressive disorcer

AbbVie's Vraylar, carrying $4B sales target, wins FDA label expansion in depression

Fierce Pharma

Mon, 12/19/22 - 10:05 pm

Where Will AbbVie Be in 3 Years?

Motley Fool

Fri, 09/30/22 - 10:50 am

AbbVie adds to Vraylar data as FDA considers depression use

Pharmaforum

Tue, 05/24/22 - 10:43 am

clinical trials

treatment-resistant depression

AbbVie doubles down on Gedeon Richter pact that brought Vraylar to the world

Fierce Biotech

Fri, 03/11/22 - 10:40 am

AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?

Endpoints

Wed, 02/23/22 - 10:24 pm

major depressive disorder

Oncology the focus for big pharma catalysts

EP Vantage

Tue, 09/28/21 - 11:19 am

Gilead Sciences

Allergan puts Vraylar on blockbuster track with new bipolar depression nod

Fierce Pharma

Tue, 05/28/19 - 12:21 pm

bipolar disorder

Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I Depression Mostly Positive

Tue, 04/3/18 - 09:09 am

bipolar disorder

Allergan, Gedeon Richter plan depression submission

BioPharma Dive

Tue, 12/19/17 - 10:21 pm

clinical depression

acute bipolar depression

Allergan hit with FDA refusal to file letter

BioPharma Dive

Mon, 09/25/17 - 07:26 pm

refuse to file letters

Allergan highlights new drug potential

BioPharma Dive

Sat, 09/10/16 - 09:50 am

Allergan's Vraylar launch a success, despite trial failure

BioPharma Dive

Tue, 08/9/16 - 10:40 am

clinical trials